We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use iwcll.org, remember your settings and improve our services. We also use cookies set by other sites to help us deliver content from their services.
Petra Langerbeins, Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938)
Home > Resources > Petra Langerbeins, Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938)
